CHPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHPT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows weak technical momentum, analyst sentiment is mostly neutral to bearish with repeated price target cuts, and the business is still not profitable. Even though some hedge funds are buying and revenue is growing, I would not call this a strong buy at the current price. For an impatient investor who does not want to wait for a better entry, the better decision is to hold off.
The chart is still bearish. MACD histogram is below zero and worsening, RSI_6 at 34.65 is weak but not yet oversold, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. Price at 6.22 is only slightly above support at 6.163 and below pivot resistance at 6.587, which suggests the stock is trading near a fragile support zone rather than in a confirmed uptrend. The short-term pattern data implies modest upside next day/week/month, but the broader trend is still weak.
["Revenue in the latest quarter increased 7.29% YoY.", "Gross margin improved to 31.47%, up 11.71% YoY.", "Hedge funds are buying, with buying activity up 212.50% over the last quarter.", "Analyst commentary notes new product launches are helping."]
["No news in the last week, so there is no fresh catalyst driving the stock higher.", "The company remains unprofitable, with net income and EPS both declining year over year.", "Several analysts cut price targets recently, including UBS, B. Riley, Roth Capital, TD Cowen, RBC, and JPMorgan.", "JPMorgan remains Underweight and highlighted demand uncertainty and hardware margin headwinds.", "Technicals are bearish and the stock is sitting near support rather than in a confirmed breakout.", "No recent congress trading data available.", "No significant insider buying trend; insiders are neutral."]
Latest reported quarter: 2026/Q4. Revenue rose to $109.32M, up 7.29% YoY, which is a positive growth sign. Gross margin improved materially to 31.47% from a year earlier, suggesting some operating improvement. However, net income was still negative at -$44.42M and EPS was -1.85, both worse year over year, so the business is still not producing profits despite better sales and margins.
Analyst sentiment has turned more cautious. Over the last few weeks, multiple firms lowered price targets: UBS to $7, B. Riley to $6, Roth to $6.50, TD Cowen to $7, RBC to $6.50, and JPMorgan to $5. Most ratings remain Neutral/Hold, with JPMorgan the most bearish at Underweight. Wall Street sees some upside from product launches and margin improvement, but the dominant view is that demand remains uncertain and profitability is still too weak to justify a bullish stance.
